SkinBioTherapeutics plc (LON: SBTX) a life sciences company focused on skin health, has today announced its half year results for the six months to 31 December 2017.
Key highlights
· Significant progress in developing the SkinBiotix® technology; successful initial lysate manufacture scale-up
· Three different formulation options for the cosmetic application are being assessed ahead of the human study scheduled in Q3 2018
· Anti-infection and eczema programmes progressing – application frequency and safe dosing levels determined
· Early stage commercial discussions with significant industry players continuing with respect to the cosmetic application
· Cash as at period end at £3.6m (2016: £0.4m)
Dr. Cath O’Neill, CEO of SkinBioTherapeutics Plc, said: “We have made significant progress in the past six months around our SkinBiotix® technology and we are on track with the advancement of all three indications in cosmetics, anti-infection and eczema.
“Our primary focus has been on developing the cosmetic application. Manufacturing scale-up and formulation is progressing to plan. As laid out at IPO, we intend to carry out the human safety study later this year.
“There is a growing awareness of our SkinBiotix® platform technology from the skin healthcare industry, based on the reputation of our team and our ‘science-led’ business approach. With continued work on our technology and the start of human studies in Q3, we are building further value for shareholders and a strong position from which to hold potential commercial discussions.”
